An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative

The objective of this analysis was to develop a semi‐mechanistic nonlinear disease progression model using an expanded set of covariates that captures the longitudinal change of Alzheimer's Disease Assessment Scale (ADAS‐cog) scores from the Alzheimer's Disease Neuroimaging Initiative study that consisted of 191 Alzheimer disease patients who were followed for 2 years. The model describes the rate of progression and baseline disease severity as a function of influential covariates. The covariates that were tested fell into 4 categories: (1) imaging volumetric measures, (2) serum biomarkers, (3) demographic and genetic factors, and (4) baseline cognitive tests. Covariates found to affect baseline disease status were years since disease onset, hippocampal volume, and ventricular volume. Disease progression rate in the model was influenced by age, total cholesterol, APOE ε4 genotype, Trail Making Test (part B) score, and current levels of impairment as measured by ADAS‐cog. Rate of progression was slower for mild and severe Alzheimer patients compared with moderate Alzheimer patients who exhibited faster rates of deterioration. In conclusion, this model describes disease progression in Alzheimer patients using novel covariates that are important for understanding the worsening of ADAS‐cog scores over time and may be useful in the future for optimizing study designs through clinical trial simulations.

[1]  Kaori Ito,et al.  Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database , 2011, Alzheimer's & Dementia.

[2]  Jeremy C Hobart,et al.  The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[3]  J. Trojanowski,et al.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.

[4]  A. Saykin,et al.  Differences in Medication Use in the Alzheimer’s Disease Neuroimaging Initiative , 2010, Drugs & aging.

[5]  C R Jack,et al.  Serial MRI and CSF biomarkers in normal aging, MCI, and AD , 2010, Neurology.

[6]  P. Passmore,et al.  Statins for the treatment of dementia , 2010, Alzheimer's & Dementia.

[7]  R. Honea,et al.  Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease , 2010, Neurology.

[8]  Kaori Ito,et al.  Disease progression meta-analysis model in Alzheimer's disease , 2010, Alzheimer's & Dementia.

[9]  K. Wesnes.  Assessing Change in Cognitive Function in Dementia: The Relative Utilities of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale and the Cognitive Drug Research System , 2008, Neurodegenerative Diseases.

[10]  Rachel L. Mistur,et al.  Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism , 2007, Proceedings of the National Academy of Sciences.

[11]  Xh Huang,et al.  Pharmacokinetic-Pharmacodynamic Modeling and Simulation. , 2007 .

[12]  F. Schmitt,et al.  A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. , 2006, Primary care companion to the Journal of clinical psychiatry.

[13]  W. M. van der Flier,et al.  Hippocampal atrophy in Alzheimer disease: Age matters , 2006, Neurology.

[14]  A. Wallin,et al.  The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  E. Niclas Jonsson,et al.  PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM , 2005, Comput. Methods Programs Biomed..

[16]  William J Jusko,et al.  Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[17]  M. Karlsson,et al.  Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis , 2002, AAPS PharmSci.

[18]  A. Tsoularis,et al.  Analysis of logistic growth models. , 2002, Mathematical biosciences.

[19]  P. Doraiswamy,et al.  The Alzheimer's Disease Assessment Scale: Evaluation of Psychometric Properties and Patterns of Cognitive Decline in Multicenter Clinical Trials of Mild to Moderate Alzheimer's Disease , 2001, Alzheimer disease and associated disorders.

[20]  J. Ashford,et al.  Modeling the time-course of Alzheimer dementia , 2001, Current psychiatry reports.

[21]  Peter L. Bonate,et al.  The Effect of Collinearity on Parameter Estimates in Nonlinear Mixed Effect Models , 1999, Pharmaceutical Research.

[22]  K. Krishnan,et al.  The Alzheimer's disease assessment scale , 1997, Neurology.

[23]  R. Kikinis,et al.  Age-related changes in intracranial compartment volumes in normal adults assessed by magnetic resonance imaging. , 1996, Journal of neurosurgery.

[24]  K. Davis,et al.  A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. , 1994, The American journal of psychiatry.

[25]  S. Gauthier,et al.  Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.

[26]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[27]  K E Peace,et al.  Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Lewis B. Sheiner,et al.  Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[29]  D. Connor,et al.  Administration and scoring variance on the ADAS-Cog. , 2008, Journal of Alzheimer's disease : JAD.

[30]  Nicholas H. G. Holford,et al.  The Visual Predictive Check Superiority to Standard Diagnostic (Rorschach) Plots , 2005 .

[31]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[32]  A. Nissinen,et al.  Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. , 1998, Neuroepidemiology.

[33]  J. Haines,et al.  Apolipoprotein E4 allele and Alzheimer disease: Examination of Allelic association and effect on age at onset in both early‐and late‐onset cases , 1995, Genetic epidemiology.